Koers Ventrus Biosciences Inc Nasdaq
Aandelen
US9228221019
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 24,2 mln. 22,41 mln. | Omzet 2025 * | 14,52 mln. 13,45 mln. | Marktkapitalisatie | 78,73 mln. 72,9 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -52 mln. -48,15 mln. | Nettowinst (verlies) 2025 * | -54 mln. -50 mln. | EV/omzet 2024 * | 3,25 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 5,42 x |
K/w-verhouding 2024 * |
-1,51
x | K/w-verhouding 2025 * |
-1,49
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 66,99% |
Recentste transcriptie over Ventrus Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 48 | 30-03-20 |
Anuj Gaggar
CTO | Chief Tech/Sci/R&D Officer | 46 | 08/11 |
William Delaney
CTO | Chief Tech/Sci/R&D Officer | 52 | 01-06-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Susan Mahony
BRD | Director/Board Member | 59 | 14-12-17 |
Gina Consylman
BRD | Director/Board Member | 52 | 20-10-20 |
William Ringo
CHM | Chairman | 78 | 01-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,88% | 80,5 mld. | |
+14,11% | 9,15 mld. | |
-14,14% | 4,9 mld. | |
+43,39% | 4,49 mld. | |
+18,90% | 4,44 mld. | |
+7,93% | 2,19 mld. | |
-28,40% | 2,13 mld. | |
+15,93% | 2,1 mld. | |
-43,17% | 1,78 mld. |
- Beurs
- Aandelen
- Koers ASMB
- Koers